Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.23
ACET's Cash-to-Debt is ranked lower than
89% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. ACET: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
ACET' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 3.56 Max: 83.22
Current: 0.23
0.16
83.22
Equity-to-Asset 0.40
ACET's Equity-to-Asset is ranked lower than
80% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACET: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.67 Max: 0.77
Current: 0.4
0.38
0.77
Debt-to-Equity 0.81
ACET's Debt-to-Equity is ranked lower than
81% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. ACET: 0.81 )
Ranked among companies with meaningful Debt-to-Equity only.
ACET' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.06 Max: 0.97
Current: 0.81
0
0.97
Debt-to-EBITDA 5.48
ACET's Debt-to-EBITDA is ranked lower than
84% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. ACET: 5.48 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ACET' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04  Med: 1.47 Max: 6.22
Current: 5.48
0.04
6.22
Interest Coverage 1.54
ACET's Interest Coverage is ranked lower than
91% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. ACET: 1.54 )
Ranked among companies with meaningful Interest Coverage only.
ACET' s Interest Coverage Range Over the Past 10 Years
Min: 1.54  Med: 14.73 Max: 147.43
Current: 1.54
1.54
147.43
Piotroski F-Score: 4
Altman Z-Score: 1.65
Beneish M-Score: -2.22
WACC vs ROIC
7.00%
2.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.17
ACET's Operating Margin % is ranked lower than
59% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. ACET: 4.17 )
Ranked among companies with meaningful Operating Margin % only.
ACET' s Operating Margin % Range Over the Past 10 Years
Min: 2.72  Med: 5.83 Max: 10.39
Current: 4.17
2.72
10.39
Net Margin % 1.07
ACET's Net Margin % is ranked lower than
65% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. ACET: 1.07 )
Ranked among companies with meaningful Net Margin % only.
ACET' s Net Margin % Range Over the Past 10 Years
Min: 1.07  Med: 3.79 Max: 6.22
Current: 1.07
1.07
6.22
ROE % 1.94
ACET's ROE % is ranked lower than
62% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. ACET: 1.94 )
Ranked among companies with meaningful ROE % only.
ACET' s ROE % Range Over the Past 10 Years
Min: 1.94  Med: 10.25 Max: 13.54
Current: 1.94
1.94
13.54
ROA % 0.79
ACET's ROA % is ranked lower than
62% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ACET: 0.79 )
Ranked among companies with meaningful ROA % only.
ACET' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 6.01 Max: 7.33
Current: 0.79
0.79
7.33
ROC (Joel Greenblatt) % 15.44
ACET's ROC (Joel Greenblatt) % is ranked higher than
55% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. ACET: 15.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACET' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.2  Med: 25.97 Max: 37.38
Current: 15.44
12.2
37.38
3-Year Revenue Growth Rate 3.10
ACET's 3-Year Revenue Growth Rate is ranked lower than
58% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ACET: 3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACET' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 5.7 Max: 14.9
Current: 3.1
0.9
14.9
3-Year EBITDA Growth Rate -3.20
ACET's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. ACET: -3.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACET' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.6  Med: 6.2 Max: 44.7
Current: -3.2
-19.6
44.7
3-Year EPS without NRI Growth Rate -30.00
ACET's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. ACET: -30.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACET' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30  Med: 6.9 Max: 59.8
Current: -30
-30
59.8
GuruFocus has detected 2 Warning Signs with Aceto Corp ACET.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACET's 30-Y Financials

Financials (Next Earnings Date: 2018-02-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ACET Guru Trades in Q4 2016

Paul Tudor Jones 15,200 sh (New)
Keeley Asset Management Corp 71,050 sh (-0.98%)
Chuck Royce 1,743,186 sh (-30.90%)
Ken Fisher 70,105 sh (-42.58%)
» More
Q1 2017

ACET Guru Trades in Q1 2017

Ken Fisher 103,850 sh (+48.13%)
Paul Tudor Jones Sold Out
Chuck Royce 146,600 sh (-91.59%)
» More
Q2 2017

ACET Guru Trades in Q2 2017

Ken Fisher 138,018 sh (+32.90%)
Chuck Royce 146,600 sh (unchged)
» More
Q3 2017

ACET Guru Trades in Q3 2017

Jim Simons 268,200 sh (New)
HOTCHKIS & WILEY 16,879 sh (New)
Chuck Royce 934,943 sh (+537.75%)
Ken Fisher 154,668 sh (+12.06%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Add 12.06%$10.28 - $17.08 $ 10.73-23%154,668
HOTCHKIS & WILEY 2017-09-30 New Buy$10.28 - $17.08 $ 10.73-23%16,879
Ken Fisher 2017-06-30 Add 32.90%$13.75 - $16.06 $ 10.73-28%138,018
Ken Fisher 2017-03-31 Add 48.13%$14.5 - $22.29 $ 10.73-37%103,850
Keeley Asset Management Corp 2016-12-31 Reduce -0.98%$15.73 - $21.97 $ 10.73-45%71,050
Ken Fisher 2016-12-31 Reduce -42.58%$15.73 - $21.97 $ 10.73-45%70,105
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XKRX:234080, TSE:4517, XKRX:183490, NAS:CPRX, BOM:500126, LSE:BMK, XKRX:002250, TSE:4577, TSXV:OGI, XKRX:214390, XKRX:008490, NAS:NEOS, TSE:4597, NAS:TTPH, TPE:3705, XKRX:000020, LSE:APH, XKRX:222040, XKRX:065660, TSX:CMED » details
Traded in other countries:AZJ.Germany,
Headquarter Location:USA
Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Ratios

vs
industry
vs
history
PE Ratio 53.65
ACET's PE Ratio is ranked lower than
64% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. ACET: 53.65 )
Ranked among companies with meaningful PE Ratio only.
ACET' s PE Ratio Range Over the Past 10 Years
Min: 8.5  Med: 20.4 Max: 91.83
Current: 53.65
8.5
91.83
Forward PE Ratio 9.68
ACET's Forward PE Ratio is ranked higher than
86% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. ACET: 9.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 53.65
ACET's PE Ratio without NRI is ranked lower than
63% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. ACET: 53.65 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACET' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.5  Med: 20.4 Max: 91.83
Current: 53.65
8.5
91.83
Price-to-Owner-Earnings 7.00
ACET's Price-to-Owner-Earnings is ranked higher than
77% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. ACET: 7.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACET' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.89  Med: 22.83 Max: 179.86
Current: 7
5.89
179.86
PB Ratio 0.80
ACET's PB Ratio is ranked higher than
91% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. ACET: 0.80 )
Ranked among companies with meaningful PB Ratio only.
ACET' s PB Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.52 Max: 3.37
Current: 0.8
0.67
3.37
PS Ratio 0.55
ACET's PS Ratio is ranked higher than
90% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. ACET: 0.55 )
Ranked among companies with meaningful PS Ratio only.
ACET' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.62 Max: 1.63
Current: 0.55
0.31
1.63
Price-to-Free-Cash-Flow 5.07
ACET's Price-to-Free-Cash-Flow is ranked higher than
85% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. ACET: 5.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACET' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.26  Med: 20.27 Max: 543
Current: 5.07
4.26
543
Price-to-Operating-Cash-Flow 4.74
ACET's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. ACET: 4.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACET' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.99  Med: 16.26 Max: 217.3
Current: 4.74
3.99
217.3
EV-to-EBIT 18.51
ACET's EV-to-EBIT is ranked higher than
50% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. ACET: 18.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 11.7 Max: 45.7
Current: 18.51
4.2
45.7
EV-to-EBITDA 9.65
ACET's EV-to-EBITDA is ranked higher than
71% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. ACET: 9.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 9.9 Max: 22.2
Current: 9.65
4
22.2
EV-to-Revenue 0.87
ACET's EV-to-Revenue is ranked higher than
87% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. ACET: 0.87 )
Ranked among companies with meaningful EV-to-Revenue only.
ACET' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 0.6 Max: 1.8
Current: 0.87
0.3
1.8
PEG Ratio 5.74
ACET's PEG Ratio is ranked lower than
73% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. ACET: 5.74 )
Ranked among companies with meaningful PEG Ratio only.
ACET' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.39 Max: 159.54
Current: 5.74
0.35
159.54
Shiller PE Ratio 15.45
ACET's Shiller PE Ratio is ranked higher than
87% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. ACET: 15.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACET' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 21.46 Max: 47.52
Current: 15.45
11.39
47.52
Current Ratio 2.06
ACET's Current Ratio is ranked lower than
57% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. ACET: 2.06 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 2.06  Med: 3.11 Max: 4.33
Current: 2.06
2.06
4.33
Quick Ratio 1.46
ACET's Quick Ratio is ranked lower than
59% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. ACET: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.93 Max: 2.76
Current: 1.46
1.21
2.76
Days Inventory 88.38
ACET's Days Inventory is ranked higher than
66% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. ACET: 88.38 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 76.62  Med: 83.66 Max: 88.38
Current: 88.38
76.62
88.38
Days Sales Outstanding 126.27
ACET's Days Sales Outstanding is ranked lower than
87% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ACET: 126.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 76.39 Max: 149.18
Current: 126.27
61.39
149.18
Days Payable 65.57
ACET's Days Payable is ranked lower than
51% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. ACET: 65.57 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.97 Max: 66.03
Current: 65.57
34.34
66.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.41
ACET's Dividend Yield % is ranked higher than
70% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. ACET: 2.41 )
Ranked among companies with meaningful Dividend Yield % only.
ACET' s Dividend Yield % Range Over the Past 10 Years
Min: 0.79  Med: 2.11 Max: 4.01
Current: 2.41
0.79
4.01
Dividend Payout Ratio 1.24
ACET's Dividend Payout Ratio is ranked lower than
84% of the 416 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACET: 1.24 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ACET' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.34 Max: 1.24
Current: 1.24
0.2
1.24
3-Year Dividend Growth Rate 2.70
ACET's 3-Year Dividend Growth Rate is ranked lower than
61% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. ACET: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ACET' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -50.8  Med: 6.9 Max: 126.4
Current: 2.7
-50.8
126.4
Forward Dividend Yield % 2.46
ACET's Forward Dividend Yield % is ranked higher than
65% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. ACET: 2.46 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.09
ACET's 5-Year Yield-on-Cost % is ranked higher than
67% of the 849 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. ACET: 3.09 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ACET' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.99  Med: 2.64 Max: 5.02
Current: 3.09
0.99
5.02
3-Year Average Share Buyback Ratio -1.50
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ACET: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.4  Med: -0.7 Max: 6.2
Current: -1.5
-4.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.64
ACET's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. ACET: 0.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACET' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 1.02 Max: 2.95
Current: 0.64
0.41
2.95
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.93
ACET's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
74% of the 85 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. ACET: 3.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ACET' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.78  Med: 1.55 Max: 7.15
Current: 3.93
0.78
7.15
Price-to-Median-PS-Value 0.85
ACET's Price-to-Median-PS-Value is ranked higher than
62% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. ACET: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACET' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 0.81 Max: 2.38
Current: 0.85
0.39
2.38
Price-to-Peter-Lynch-Fair-Value 8.13
ACET's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. ACET: 8.13 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ACET' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.26 Max: 8.57
Current: 8.13
0.4
8.57
Earnings Yield (Greenblatt) % 5.36
ACET's Earnings Yield (Greenblatt) % is ranked higher than
66% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. ACET: 5.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACET' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 8.6 Max: 23.6
Current: 5.36
2.2
23.6
Forward Rate of Return (Yacktman) % 15.56
ACET's Forward Rate of Return (Yacktman) % is ranked higher than
64% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. ACET: 15.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACET' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 12.45 Max: 48.8
Current: 15.56
-1.4
48.8

More Statistics

Revenue (TTM) (Mil) $695.56
EPS (TTM) $ 0.20
Beta1.09
Short Percentage of Float6.30%
52-Week Range $8.29 - 22.46
Shares Outstanding (Mil)30.64

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 748 775 758
EPS ($) 1.14 1.23 1.21
EPS without NRI ($) 1.14 1.23 1.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.00%
Dividends per Share ($) 0.26 0.26 0.26

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}